

**FRI0233 DOES GOUT PROTECT FROM PARKINSON'S DISEASE: A CASE-CONTROL STUDY FROM AN URBAN POPULATION**

C. Diaz-Torne<sup>1</sup>, M.A. Pou<sup>2</sup>, F. Orfila<sup>3</sup>, S. Jeria<sup>4</sup>, S. Fernandez<sup>4</sup>, H. Park<sup>4</sup>, I. Castellvi<sup>4</sup>, H. Corominas<sup>4</sup>. <sup>1</sup>Unitat de Reumatologia, Hospital de la Santa Creu i Sant Pau; <sup>2</sup>EAP Encants. ICS; <sup>3</sup>IDiAP Jordi Gol. ICS; <sup>4</sup>Unitat de Reumatologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

**Background:** It has been demonstrated that hyperuricemia protects from Parkinson's disease (PD), but this relation is controversial in patients with gout. Inflammatory properties of urate monosodium(UMS) crystals deposition that appears when uric acid(UA) levels exceed its solubility faces antioxidant and neuroprotective features of soluble UA. Both, UMS crystals deposition and hyperuricemia coexist in gouty patients.

There is several data that demonstrates that hyperuricemia protects from Parkinson's disease (PD). Results from different studies about the relation between them are controversial. Inflammatory properties of the urate crystals faces antioxidant and neuroprotective features of soluble UA. Both, UMS crystals and hyperuricemia coexist in gouty patients.

**Objectives:** To study if gout protects from Parkinson disease in a mediterranean urban population.

**Methods:** Primary care based matched case-control study. It has been carried out using the electronic clinical record database from the public health (Institut Català de la Salut) of the city of Barcelona. The database contains anonymous data from almost 1 million and a half people. Just people that were 40 years or older were studied. Were considered cases patients with a PD diagnose, or taking high specific anti-Parkinson's drugs (like l-dope, rasagiline, selegiline...), between 2006 and 2016. For every case we randomly selected four controls matched by gender and age. Data on risk factors was also collected for each individual (diabetes mellitus, hypertension, hypercholesterolemia and tobacco consumption before the PD diagnose), as well as age and gender. A multivariate logistic regression model was used to study the association of gout and PD adjusted by the presence of other risk factors. Adjusted Odds Ratios (aOR) and their 95% CI are provided.

**Results:** 21 789 persons with a PD diagnose and 87 156 controls were included. Mean age was 75.5 (SD 10.9) years. 55.6% were females. 2.5% of PD patients had a previous gout diagnose, compared to 4.8% of controls (p<0.001). Multivariate Logistic regression model showed for gout: aOR=0.55 (0.50–0.61). Diabetes mellitus: aOR=1.18 (1.14–1.23); hypertension: aOR=0.7 (0.72–0.77); tobacco: aOR=0.55 (0.52–0.58); high cholesterol levels: aOR=0.60 (0.58–0.61).

**Conclusions:** Gout shows a protective effect on the development of Parkinson's disease, pointing that the antioxidant and neuro protective effect of UA seems to overcome its inflammatory properties in gouty patients.

Gout shows a protective effect on the development of Parkinson's disease, pointing that the antioxidant and neuro protective effect of UA seems to overcome its inflammatory properties in gouty patients.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.4666

**FRI0234 SEL-212: SELECTIVE MITIGATION OF ANTI-DRUG ANTIBODIES AGAINST PEGSITICASE TO CONTROL SERUM URIC ACID IN HYPERURICEMIC SUBJECTS**

E. Sands<sup>1</sup>, A.J. Kivitz<sup>2</sup>, L. Johnston PhD<sup>1</sup>, W. DeHaan<sup>3</sup>, T.K. Kishimoto<sup>1</sup>. <sup>1</sup>Selecta Biosciences, Watertown; <sup>2</sup>Altoona Center for Clinical Research, Duncansville, PA; <sup>3</sup>480 Arsenal Way, Selecta Biosciences, Watertown, USA

**Background:** We previously reported initial Phase 2 study results for 60 gout patients treated with SEL-212, a novel combination treatment comprised of pegsiticase (pegylated uricase) co-administered with a synthetic vaccine particle encapsulating rapamycin (SVP-R).<sup>1</sup> SEL-212 was well-tolerated, mitigated the formation of anti-drug antibodies, and enabled sustained control of serum uric acid (sUA) levels in most subjects.<sup>1</sup> In this ongoing study, new treatment cohorts involving higher SVP-R dose levels and extended combination regimens were introduced.

**Objectives:** To assess the tolerability and impact on sUA levels and ADA formation of escalated and expanded doses of SEL-212, designed to be the first non-immunogenic uricase therapy for refractory gout.

**Methods:** Patients with symptomatic gout ( $\geq 1$  tophus, gout flare within 6 months or gouty arthropathy) and elevated sUA ( $\geq 6$  mg/dL) were enrolled to SEL-212 treatment (n=6–12 pts/cohort) of fixed doses of pegsiticase (0.2 mg/kg or 0.4 mg/kg) alone or co-administered with SVP-R (0.05, 0.08, 0.1, 0.125, and 0.15 mg/kg). SEL-212 was infused in 28 day cycles x3 doses followed by challenge with pegsiticase alone on 28 day cycles x2 doses. In addition, 2 cohorts were added that

extended the combination treatment with SVP-R to all five q28 doses of pegsiticase. ADAs and sUA were assessed at baseline and 7, 14, 21, and 30 days after each dose to Day 140. Safety was monitored continuously.

**Results:** As previously reported, 5 of 6 patients dosed with pegsiticase alone developed ADAs after a single dose, correlating with loss of sUA control by 30 days. The addition of SVP-R to pegsiticase showed a dose-dependent inhibition of ADAs, enabling prolonged control of sUA levels. At a mid-dose of 0.1 mg/kg SVP-R, combined with either 0.2 or 0.4 mg/kg pegsiticase, the majority of patients showed sustained control of sUA through 18 weeks. However, control of ADAs and sUA tapered off in some patients by week 20, after two injections of pegsiticase alone. Preliminary results of treatment at increased SVP-R doses (0.125–0.15 mg/kg) are consistent with Phase 1b data indicating that higher doses of the SVP-R will increase the percentage of patients that remain ADA free. These results also suggest that extending treatment to 5 doses of SVP-R and pegsiticase may enable more subjects to complete the 5 month treatment with sustained reductions in sUA. In addition to mitigating immunogenicity, patients treated with SVP-R experienced a low rate of gout flares, with less than 25% of patients experiencing flares during the first month after treatment, despite profound drop in sUA level, and continued reduction was observed during months 2–5. SEL-212 has been generally well tolerated at clinically active dose levels and infusion reactions observed with repeat dosing were reduced with increasing doses of SVP-R.

**Conclusions:** SEL-212 has been well tolerated, mitigated immunogenicity, and sustained control of sUA levels. Escalation of the SVP-R component of SEL-212 may enhance the duration of sUA and ADA suppression without increased risk.

**REFERENCE:**

[1] Sands, et al. EULAR Annual European Congress 2017. Poster THU0402.

**Disclosure of Interest:** E. Sands Employee of: Selecta Biosciences, A. Kivitz: None declared, L. Johnston PhD Employee of: Selecta Biosciences, W. DeHaan Employee of: Selecta Biosciences, T. Kishimoto Employee of: Selecta Biosciences

**DOI:** 10.1136/annrheumdis-2018-eular.7396

**FRI0235 EFFECT OF SERUM URIC ACID (SUA) ON GOUT FLARES (GF) AND TOPHI RESOLUTION IN GOUT PATIENTS. POOLED POST HOC ANALYSIS OF CLEAR 1 & CLEAR 2 TRIALS**

F. Perez-Ruiz<sup>1</sup>, P. Richette<sup>2</sup>, R.G. Karra<sup>3</sup>, I. Wild<sup>3</sup>, H. Hagedorn<sup>3</sup>, P. Kandaswamy<sup>3</sup>, T. Bardin<sup>2</sup>. <sup>1</sup>Rheumatology Division of Cruces Hospital and University of the Basque Country, Baracaldo, Spain; <sup>2</sup>Université Paris Diderot, Paris, France; <sup>3</sup>Grünenthal GmbH, Aachen, Germany

**Background:** Gout is caused by crystal deposition due to persistent hyperuricemia. EULAR<sup>1</sup> and other guidelines recommend a target sUA of <5–6 mg/dL (0.30 to 0.36 mmol/L) depending on severity. Despite physiological plausibility and abundant literature evidence there is an absence of consensus among physicians on the targets and necessity of long term urate lowering therapy (ULT)<sup>2</sup>.

**Objectives:** To investigate the effects of sUA and target sUA <5–6 mg/dl with respect to the occurrence of GF, flares requiring treatment (GFRT) and the percent change in the area of tophi (TR) from baseline irrespective of treatment arms.

**Methods:** Data of 1213 patients (PT) was pooled from CLEAR trials<sup>3&4</sup>, two randomized, double-blind, placebo-controlled Phase 3 studies that evaluated Lesinurad 200/400 mg daily in combination with allopurinol vs allopurinol. Prophylaxis for flares was given from baseline to month (M) 5. PT who met the sUA target of <5–6 mg/dl at M 6 and 12 were compared against those not on target with respect to the TR from baseline using a Wilcoxon test. In addition, the mean sUA measurements for PT with or without GFs and GFRT was compared at M 6 and 12 using a t-test.

**Results:** PT with sUA on target <5–6 mg/dl showed a larger decrease (increase in percent reduction) in area of tophi with a difference of 27.9%, and 17.3% at M 12 only compared to the PT not on target (table 1). The mean sUA levels were 0.227 mg/dL lower for PT with GF and 0.389 mg/dL lower for PT with GFRT compared to PT without GF and GFRT at M 6 (table 2), but not at M 12.

**Abstract FRI0235 – Table 1.** Percent Change from baseline Area of tophi vs. SUA on target <5–6 mg/dL at M 6 and 12

sUA (mg/dL) n=M6/M12	M6		p-value#	M12		p-value#
	Median	(Q1, Q3)		Median	(Q1, Q3)	
<5 (n=31/36)	-22.1	(-46.4, 5.63)	0.78	-59.6	(-98.3, -27.5)	0.01
$\geq 5$ (n=93/87)	-22.2	(-56.7, 6.91)		-31.7	(-77.4, 13.06)	
<6 (n=63/66)	-23.8	(-56.7, 1.59)	0.64	-49.0	(-93.3, -12.9)	0.06
$\geq 6$ (n=61/57)	-19.2	(-42.5, 10.30)		-31.7	(-60.1, 13.06)	